HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA):... von Llombart-Cussac, Antonio, MD, Cortés, Javier, MD, Paré, Laia, PhD, Galván, Patricia, BS, Bermejo, Begoña, MD, Martínez, Noelia, MD, Vidal, Maria, MD, Pernas, Sònia, MD, López, Rafael, MD, Muñoz, Montserrat, MD, Nuciforo, Paolo, MD, Morales, Serafín, MD, Oliveira, Mafalda, MD, de la Peña, Lorena, PhD, Peláez, Alexandra, MD, Prat, Aleix, Dr

Volltext

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade von Brasó-Maristany, Fara, Griguolo, Gaia, Pascual, Tomás, Paré, Laia, Nuciforo, Paolo, Llombart-Cussac, Antonio, Bermejo, Begoña, Oliveira, Mafalda, Morales, Serafín, Martínez, Noelia, Vidal, Maria, Adamo, Barbara, Martínez, Olga, Pernas, Sonia, López, Rafael, Muñoz, Montserrat, Chic, Núria, Galván, Patricia, Garau, Isabel, Manso, Luis, Alarcón, Jesús, Martínez, Eduardo, Gregorio, Sara, Gomis, Roger R., Villagrasa, Patricia, Cortés, Javier, Ciruelos, Eva, Prat, Aleix

Volltext

Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial von Fullana, Bartomeu, Morales, Serafín, Petit, Anna, Alay, Ania, Verdaguer, Helena, Climent, Fina, Navarro-Perez, Valentí, Cejuela, Mónica, Galvan, Patricia, Gumà, Anna, Llombart-Cussac, Antonio, Cordero, David, Casanovas, Oriol, Prat, Aleix, Gil-Gil, Miguel, Pernas, Sonia

Volltext

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-po... von Schmid, Peter, Cortes, Javier, Joaquim, Ana, Jañez, Noelia Martínez, Morales, Serafín, Díaz-Redondo, Tamara, Blau, Sibel, Neven, Patrick, Lemieux, Julie, García-Sáenz, José Ángel, Hart, Lowell, Biyukov, Tsvetan, Baktash, Navid, Massey, Dan, Burris, 3rd, Howard A, Rugo, Hope S

Volltext

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade von Prat, Aleix, Pascual, Tomás, De Angelis, Carmine, Gutierrez, Carolina, Llombart-Cussac, Antonio, Wang, Tao, Cortés, Javier, Rexer, Brent, Paré, Laia, Forero, Andres, Wolff, Antonio C, Morales, Serafín, Adamo, Barbara, Brasó-Maristany, Fara, Vidal, Maria, Veeraraghavan, Jamunarani, Krop, Ian, Galván, Patricia, Pavlick, Anne C, Bermejo, Begoña, Izquierdo, Miguel, Rodrik-Outmezguine, Vanessa, Reis-Filho, Jorge S, Hilsenbeck, Susan G, Oliveira, Mafalda, Dieci, Maria Vittoria, Griguolo, Gaia, Fasani, Roberta, Nuciforo, Paolo, Parker, Joel S, Conte, PierFranco, Schiff, Rachel, Guarneri, Valentina, Osborne, C Kent, Rimawi, Mothaffar F

Volltext

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic bre... von Schmid, Peter, Sablin, Marie-Paule, Bergh, Jonas, Im, Seock-Ah, Lu, Yen-Shen, Martínez, Noelia, Neven, Patrick, Lee, Keun Seok, Morales, Serafín, Pérez-Fidalgo, J Alejandro, Adamson, Douglas, Gonçalves, Anthony, Prat, Aleix, Jerusalem, Guy, Schlieker, Laura, Espadero, Rosa-Maria, Bogenrieder, Thomas, Huang, Dennis Chin-Lun, Crown, John, Cortés, Javier

Volltext

Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study von Martín, Miguel, Loibl, Sibylle, von Minckwitz, Gunter, Morales, Serafín, Martinez, Noelia, Guerrero, Angel, Anton, Antonio, Aktas, Bahriye, Schoenegg, Winfried, Muñoz, Montserrat, Garcia-Saenz, José Ángel, Gil, Miguel, Ramos, Manuel, Margeli, Mireia, Carrasco, Eva, Liedtke, Cornelia, Wachsmann, Grischa, Mehta, Keyur, De la Haba-Rodriguez, Juan R

Volltext

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study von Alés-Martínez, José Enrique, Balmaña, Judith, Sánchez-Rovira, Pedro, Salvador Bofill, Francisco Javier, García Sáenz, Jose Ángel, Pimentel, Isabel, Morales, Serafín, Fernández-Abad, María, Lahuerta Martínez, Ainhara, Ferrer, Neus, Zamora, Pilar, Bermejo, Begoña, Díaz-Redondo, Tamara, López-Ceballos, María Helena, Galán, María, Pérez-Escuredo, Jhudit, Calabuig, Laura, Sampayo, Miguel, Pérez-Garcia, José Manuel, Cortés, Javier, Llombart-Cussac, Antonio

Volltext

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opt... von Gavilá, Joaquín, Oliveira, Mafalda, Pascual, Tomás, Perez-Garcia, Jose, Gonzàlez, Xavier, Canes, Jordi, Paré, Laia, Calvo, Isabel, Ciruelos, Eva, Muñoz, Montserrat, Virizuela, Juan A, Ruiz, Isabel, Andrés, Raquel, Perelló, Antonia, Martínez, Jerónimo, Morales, Serafín, Marín-Aguilera, Mercedes, Martínez, Débora, Quero, Juan C, Llombart-Cussac, Antonio, Prat, Aleix

Volltext

Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research von Pont, Mariona, Marqués, Marta, Sorolla, Maria Alba, Parisi, Eva, Urdanibia, Izaskun, Morales, Serafín, Salud, Antonieta, Sorolla, Anabel

Volltext

Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer von Ciruelos, Eva María, Díaz, María Nieves, Isla, María Dolores, López, Rafael, Bernabé, Reyes, González, Encarnación, Cirauqui, Beatriz, Coves, Juan, Morales, Serafín, Arcediano, Alberto, Barneto, Isidoro, Cerezuela, Pablo, Illarramendi, José Juan, Morales, Cristina, Ponce, Santiago

Volltext

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial von Pascual, Tomás, Oliveira, Mafalda, Villagrasa, Patricia, Ortega, Vanesa, Paré, Laia, Bermejo, Begoña, Morales, Serafín, Amillano, Kepa, López, Rafael, Galván, Patricia, Canes, Jordi, Salvador, Fernando, Nuciforo, Paolo, Rubio, Isabel T., Llombart-Cussac, Antonio, Di Cosimo, Serena, Baselga, José, Harbeck, Nadia, Prat, Aleix, Cortés, Javier

Volltext

Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers? von Marqués, Marta, Sorolla, Maria Alba, Urdanibia, Izaskun, Parisi, Eva, Hidalgo, Iván, Morales, Serafín, Salud, Antonieta, Sorolla, Anabel

Volltext

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in th... von Martín, Miguel, Zielinski, Christoph, Ruiz-Borrego, Manuel, Carrasco, Eva, Ciruelos, Eva M., Muñoz, Montserrat, Bermejo, Begoña, Margelí, Mireia, Csöszi, Tibor, Antón, Antonio, Turner, Nicholas, Casas, María I., Morales, Serafín, Alba, Emilio, Calvo, Lourdes, de la Haba-Rodríguez, Juan, Ramos, Manuel, Murillo, Laura, Santaballa, Ana, Alonso-Romero, José L., Sánchez-Rovira, Pedro, Corsaro, Massimo, Huang, Xin, Thallinger, Christiane, Kahan, Zsuzsanna, Gil-Gil, Miguel

Volltext

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Fina... von Gil-Gil, Miguel J., Bellet, Meritxell, Bergamino, Milana, Morales, Serafín, Barnadas, Agustí, Manso, Luís, Saura, Cristina, Fernández-Ortega, Adela, Garcia-Martinez, Elena, Martinez-Jañez, Noelia, Melé, Mireia, Villagrasa, Patricia, Celiz, Pamela, Perez Martin, X., Ciruelos, Eva, Pernas, Sonia

Volltext

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP) von Manso, Luis, Hernando, Cristina, Galán, María, Oliveira, Mafalda, Cabrera, Miguel A., Bratos, Raquel, Rodríguez, César A., Ruiz-Borrego, Manuel, Blanch, Salvador, Llombart-Cussac, Antonio, Delgado-Mingorance, Juan I., Álvarez-Busto, Iñaki, Gallegos, Isabel, González-Cortijo, Lucía, Morales, Serafín, Aguirre, Elena, Hernando, Blanca A., Ballesteros, Ana, Alés-Martínez, José E., Reboredo, Cristina, Oltra, Amparo, González-Cao, María, Santisteban, Marta, Malón, Diego, Echeverría, Isabel, García-Garre, Elisa, Vega, Estela, Servitja, Sònia, Andrés, Raquel, Robles, Carlos E., López, Rafael, Galve, Elena, Echarri, María J., Legeren, Marta, Moreno, Fernando

Volltext

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer von Turner, Nicholas C., Oliveira, Mafalda, Howell, Sacha J., Dalenc, Florence, Cortes, Javier, Gomez Moreno, Henry L., Hu, Xichun, Jhaveri, Komal, Krivorotko, Petr, Loibl, Sibylle, Morales Murillo, Serafin, Okera, Meena, Park, Yeon Hee, Sohn, Joohyuk, Toi, Masakazu, Tokunaga, Eriko, Yousef, Samih, Zhukova, Lyudmila, de Bruin, Elza C., Grinsted, Lynda, Schiavon, Gaia, Foxley, Andrew, Rugo, Hope S.

Volltext

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cance... von Llombart-Cussac, Antonio, Bermejo, Begoña, Villanueva, Cristian, Delaloge, Suzette, Morales, Serafín, Balmaña, Judith, Amillano, Kepa, Bonnefoi, Hervé, Casas, Ana, Manso, Luis, Roché, Henri, Gonzalez-Santiago, Santiago, Gavilá, Joaquín, Sánchez-Rovira, Pedro, Di Cosimo, Serena, Harbeck, Nadia, Charpentier, Eric, Garcia-Ribas, Ignacio, Radosevic-Robin, Nina, Aura, Claudia, Baselga, Jose

Volltext

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer von Pascual, Tomás, Martin, Miguel, Fernández-Martínez, Aranzazu, Paré, Laia, Alba, Emilio, Rodríguez-Lescure, Álvaro, Perrone, Giuseppe, Cortés, Javier, Morales, Serafín, Lluch, Ana, Urruticoechea, Ander, González-Farré, Blanca, Galván, Patricia, Jares, Pedro, Rodriguez, Adela, Chic, Nuria, Righi, Daniela, Cejalvo, Juan Miguel, Tonini, Giuseppe, Adamo, Barbara, Vidal, Maria, Villagrasa, Patricia, Muñoz, Montserrat, Prat, Aleix

Volltext

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Res... von Llombart-Cussac, Antonio, Ramos, Manuel, Dalmau, Elsa, García-Saenz, José A, González-Farré, Xavier, Murillo, Laura, Calvo, Lourdes, Morales, Serafín, Carañana, Vicente, González, Ana, Fernández-Morales, Luis A, Moreno, Fernando, Casas, Mª Isabel, Angulo, Mª del Mar, Cámara, Mª Carmen, Garcia-Mace, Ana I, Carrasco, Eva, Jara-Sánchez, Carlos

Volltext